Literature DB >> 18596117

Consistent control of mineral and bone disorder in incident hemodialysis patients.

Mark D Danese1, Vasily Belozeroff, Karen Smirnakis, Kenneth J Rothman.   

Abstract

BACKGROUND AND OBJECTIVES: In 2003, the National Kidney Foundation introduced guidelines for the control of parathyroid hormone, calcium, and phosphorus in hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A cohort study was conducted of 22,937 incident hemodialysis patients who were identified from a large national provider between July 1, 2000, and June 30, 2002, and followed through June 30, 2004. Consistent achievement was determined (1) as the simultaneous control of multiple markers over time and (2) as the time in target for each marker during the first year of dialysis. Mortality risk was assessed with Cox proportional hazards models.
RESULTS: In the simultaneous control analysis, patients who achieved target for none of the markers had a 51% greater risk for death than those who achieved target for all three markers (reference group). Patients who achieved any target for any single marker had a 35 to 39% higher risk for death, and patients who achieved target for any two of the three markers had a 15 to 21% higher risk for death compared with the reference group. In the time in target analysis, patients with parathyroid hormone in target for 4 quarters had a 25% lower risk for death compared with those who did so for <or=1 quarter (reference group). Patients with calcium in target for 4 quarters had a 14% lower risk, and patients with phosphorus in target for 4 quarters had a 38% lower risk.
CONCLUSIONS: Consistent control of the markers of bone metabolism and disease within published targets is a strong predictor of survival in hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596117      PMCID: PMC2518803          DOI: 10.2215/CJN.01060308

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  23 in total

Review 1.  Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies.

Authors:  Sander Greenland
Journal:  Am J Epidemiol       Date:  2004-08-15       Impact factor: 4.897

Review 2.  Impact of the new K/DOQI guidelines.

Authors:  Garabed Eknoyan; Nathan W Levin
Journal:  Blood Purif       Date:  2002       Impact factor: 2.614

3.  Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale.

Authors:  M Gallieni; D Brancaccio; F Antonucci; G Bellinghieri; P Carpani; M Cozzolino; F D'Agostino; G Del Mastro; A Mallamace; B Memoli
Journal:  Clin Nephrol       Date:  2000-03       Impact factor: 0.975

4.  Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation.

Authors:  M M Avram; N Mittman; M M Myint; P Fein
Journal:  Am J Kidney Dis       Date:  2001-12       Impact factor: 8.860

5.  Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients.

Authors:  Jinn-Yuh Guh; Hung-Chun Chen; Hung-Yi Chuang; Su-Chen Huang; Li-Chu Chien; Yung-Hsiung Lai
Journal:  Am J Kidney Dis       Date:  2002-06       Impact factor: 8.860

6.  Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.

Authors:  María D Arenas; Fernando Alvarez-Ude; Vicente Torregrosa; María T Gil; María A Carretón; Analía Moledous; Carlos Nuñez; Ramón Devesa; Begoña Albiach
Journal:  J Nephrol       Date:  2007 Jul-Aug       Impact factor: 3.902

7.  Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes.

Authors:  Lesley A Stevens; Ognjenka Djurdjev; Savannah Cardew; E C Cameron; Adeera Levin
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race.

Authors:  Ali Owda; Huda Elhwairis; Sridhar Narra; Heather Towery; Sayed Osama
Journal:  Ren Fail       Date:  2003-07       Impact factor: 2.606

9.  Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Authors:  Ming Teng; Myles Wolf; Edmund Lowrie; Norma Ofsthun; J Michael Lazarus; Ravi Thadhani
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

10.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

View more
  40 in total

1.  The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.

Authors:  Dan Li; Leping Shao; Haiyan Zhou; Wei Jiang; Wei Zhang; Yan Xu
Journal:  Endocrine       Date:  2012-06-06       Impact factor: 3.633

Review 2.  Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

3.  Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

Authors:  Tadao Akizawa; Ryo Kido; Masafumi Fukagawa; Yoshihiro Onishi; Takuhiro Yamaguchi; Takeshi Hasegawa; Shunichi Fukuhara; Kiyoshi Kurokawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

4.  Dialysis: Is the road to survival paved with good mineral management?

Authors:  Hirotaka Komaba; Masafumi Fukagawa
Journal:  Nat Rev Nephrol       Date:  2011-04       Impact factor: 28.314

Review 5.  [Management of secondary hyperparathyroidism-current impact of parathyroidectomy].

Authors:  Emanuel Zitt; Karl Lhotta
Journal:  Wien Med Wochenschr       Date:  2016-02-25

6.  Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

Authors:  Bojan Kovacevic; Mile Ignjatovic; Vladan Zivaljevic; Vladimir Cuk; Milena Scepanovic; Zaklina Petrovic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2012-01-13       Impact factor: 3.445

7.  CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis.

Authors:  Geoffrey A Block; Ryan D Kilpatrick; Kimberly A Lowe; Wenli Wang; Mark D Danese
Journal:  Clin J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 8.237

8.  Effects of phosphate binders in moderate CKD.

Authors:  Geoffrey A Block; David C Wheeler; Martha S Persky; Bryan Kestenbaum; Markus Ketteler; David M Spiegel; Matthew A Allison; John Asplin; Gerard Smits; Andrew N Hoofnagle; Laura Kooienga; Ravi Thadhani; Michael Mannstadt; Myles Wolf; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2012-07-19       Impact factor: 10.121

9.  Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.

Authors:  Emanuel Zitt; Christine Jäger; Alexander R Rosenkranz; Manfred Eigner; Katharina Kodras; Josef Kovarik; Helmut Graf; Frank Pétavy; Sabine Horn; Bruno Watschinger
Journal:  Wien Klin Wochenschr       Date:  2011-01-21       Impact factor: 1.704

10.  Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.

Authors:  Melissa Soohoo; Mingliang Feng; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jialin Wang; Vanessa A Ravel; Steven Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2016-03-08       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.